RecruitingPhase 1NCT05372640
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Studying NUT midline carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jia LuoDana-Farber - Harvard Cancer Center LAO
- Intervention
- Abemaciclib(drug)
- Enrollment
- 45 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2026
Study locations (7)
- Keck Medicine of USC Koreatown, Los Angeles, California, United States
- Los Angeles General Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05372640 on ClinicalTrials.govOther trials for NUT midline carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07050186Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT CarcinomaNorthwestern University
- ACTIVE NOT RECRUITINGNCT07459127Multicenter Retrospective Cohort of Pulmonary NUT CarcinomaThree Gorges Hospital of Chongqing University
- RECRUITINGNCT05265429Biology of Young Lung Cancer Study: The YOUNG LUNG StudyDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT05019716Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)